A Phase 1b Open-Label, Dose Escalation Study of PRTX-100 in Adult Patients With Persistent/Chronic Immune Thrombocytopenia

Trial Profile

A Phase 1b Open-Label, Dose Escalation Study of PRTX-100 in Adult Patients With Persistent/Chronic Immune Thrombocytopenia

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 31 Aug 2017

At a glance

  • Drugs Staphylococcal-protein-A (Primary)
  • Indications Immune thrombocytopenic purpura
  • Focus Adverse reactions
  • Sponsors Protalex
  • Most Recent Events

    • 29 Aug 2017 According to a Protalex media release, Protalex has opened seven new clinical trial sites in the U.K.The first U.K. patient has enrolled.
    • 29 Aug 2017 According to a Protalex media release, following a planned interim analysis of data from the second dose cohort of this trial, enrollment in the third cohort has been initiated.The first patient in the third cohort was dosed at 12.0 µg/kg.
    • 07 Jun 2017 According to a Protalex media release, the company has started patients screening in the United Kingdom. With this expansion, the company now has more than 20 sites worldwide open for patient enrollment.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top